HUTCHMED (China) Ltd secured a conditional HUTCHMED savolitinib China approval on Wednesday, as the National Medical Products Administration (NMPA) cleared ORPATHYS for locally advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma in patients with MET amplification. Shares in HCM jumped 11.7% to 179.25p.
HUTCHMED Savolitinib China Approval: Trial Data and Market Scope
According to a HUTCHMED press release, the NMPA decision is supported by a pivotal Phase II registration study. As of the 8 October 2025 data cut-off, the independently reviewed objective response rate was 32.3%, the disease control rate was 63.1%, median duration of response was 9.7 months, and median progression-free survival was 4.0 months.
HUTCHMED says savolitinib is the first selective MET inhibitor approved in China for this indication, targeting patients who have failed at least two prior systemic treatments. MET amplification accounts for an estimated 4 to 6% of gastric cancer cases, with around 18,000 MET-amplified gastric cancer diagnoses in China each year.
James Latham Revenue Climbs as James Cropper Refinances
Timber supplier James Latham (LON: LTHM) reported full-year revenue of £393.0 million for the year ended 31 March 2026, up 7.2% from £366.6 million a year earlier, according to its preliminary results filing. Pre-tax profit rose from £24.3 million to £25.1 million. Gross margin edged down to 16.5% from 16.8%.
The board declared a final dividend of 28.6p per share, taking the full-year total to 36.7p, up from 35.25p. Net assets increased to £232.3 million. Cash stood at £51.2 million at the end of March 2026. The company said positive momentum had continued into the new financial year, though Middle East conflict could create supply uncertainties. The share price rose 7.84% to £11.
Advanced materials and paper producer James Cropper (LON: CRPR) refinanced its debt, including a new invoice discounting facility of up to £15 million. A one-off pension funding charge of £600,000 was agreed, and the next valuation has been brought forward to March 2027. Shares gained 8.57% to 380p.
ActiveOps Statutory Loss Obscures Software Growth
Decision intelligence software provider ActiveOps (LON: AOM) reported total revenue of £45.0 million for the year ended 31 March 2026, up 48% from £30.5 million, its results filing shows. Software and subscription revenue rose 42% to £38.0 million. Adjusted EBITDA climbed 72% to £4.3 million.
The statutory result was a loss before tax of £2.0 million, against a profit of £1.3 million in the prior year. The swing reflects £3.0 million in exceptional costs tied to the acquisition of Enlighten Group. The snippet’s reference to a £2.4 million pre-tax profit figure relates to an adjusted measure; the primary filing records the statutory loss. Net revenue retention was 119% and annualised recurring revenues stand at £41.5 million.
ActiveOps also received the $10 million payment from the sale of its WorkiQ trademarks to Microsoft, agreed on 2 April 2026, after the financial year end. Cash was £23.8 million at year end. Shares fell 9.52% to 237.5p.
Other Movers and Ex-Dividends
US oil and gas producer Zephyr Energy (LON: ZPHR) leased an additional 2,294 acres in the Paradox Basin in Utah, north of its White Sands unit. Total acreage now exceeds 72,000 acres. Shares rose 8.19% to 3.7p.
Sintana Energy (LON: SEI) said it is progressing towards drilling in Namibia, Uruguay, and Angola, with up to six results expected over the next 18 months. Activity is set to begin on the PEL 83 licence in Namibia, where Sintana carries a 4.9% stake at no cost. Cash stood at $16.1 million at end-June 2026, with $6.75 million expected from legacy deals. Shares gained 5.56% to 19p.
Huddled Group (LON: HUD) said its retail offer at 0.4p per share was nearly three times subscribed. It accepted £200,000, double the amount sought, taking total funds raised to £1.51 million. Shares recovered 5.26% to 0.5p.
On the downside, Mercantile Ports & Logistics (LON: MPL) said a hearing before the National Company Law Tribunal concerning Karanja Terminal & Logistics was adjourned to 7 August. Shares fell 12.9% to 1.35p. Ultimate Products (LON: ULTP) founder Simon Showman sold 165,681 shares at 45.9p each, with his three adult children each acquiring one-third. Shares slipped 2.98% to 45.6p.
Among ex-dividends, BP Marsh (LON: BPM) pays a final dividend of 6.98p per share, Next 15 Group (LON: NFG) pays 10.6p, and Camellia (LON: CAM) pays 260p. Microlise (LON: SAAS) pays a final dividend of 1.3p per share.
With savolitinib now the first approved selective MET inhibitor in China for this indication, the next catalyst for HUTCHMED will be commercial launch execution in a market where MET-amplified gastric cancer affects an estimated 18,000 patients a year.